CIML NK Cell in Head & Neck Cancer

NCT04290546 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

11

Enrollment

OTHER

Sponsor class

Conditions

Squamous Cell Carcinoma of the Head and Neck
Recurrent Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: Interleukin-15 Superagonist (N-803)
BIOLOGICAL: CIML NK cell Infusion
DRUG: Ipilimumab
DRUG: Cetuximab

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]
[object Object]
[object Object]